Close 2026-08-21 1267 scanned A

JLHL

Jupiter Life Line Hospital
HealthcareSmall capRs 2,031 crRs 6.0 cr traded a day
Close on 2026-08-21
309.75
−2.50%
52-week range75% of the way up
239.98332.40
Market cap
2,031 cr
P/E (TTM)
10.9×
industry 44×
EPS (TTM)
28.39
Revenue YoY
+43.1%
Q1 FY27
Profit YoY
-15.9%
Net margin
9.1%
-6.4pt vs a year ago
Growth trend
+25.5pt
vs last quarter’s YoY
1 month
-1.6%
Below 52w high
7.3%
RSI (14)
41
Daily swing
3.4%
average true range
Volume
0.4×
vs 20-day average
Traded
Rs 6 cr
median day
Close200-day averageMaterial filing
250300Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
−1.90%
1 month
−1.64%
3 months
+15.78%
6 months
+18.61%
1 year
+6.97%

The read

written from the numbers on this page
The evidence leans constructive5 supporting, 1 against, 0 worth knowing

Supporting

  • trading 14% above its 200-day average
  • up 7% over twelve months
  • 3 independent kinds of evidence agree today, which is uncommon
  • revenue grew 43% year on year in the quarter ending 2026-06-30
  • priced at 11× earnings against an industry median of 44× — 75% below its peers

Against

  • net margin has narrowed from 15.5% to 9.1% across four quarters

Worth knowing

  • nothing the data supports either way
What would change this read: a close below 273, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

How it has performed

price return over each window, measured against zero
-1.9%1W-1.6%1M+15.8%3M+18.6%6M+7.0%1Y

What the scans say today

3 of 47 matched on 2026-08-21
JLHL matches 3 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

Valuation against its own history

500 sessions since 2024-09-06
median 10×
11×
now 11×
JLHL trades at 11× trailing earnings, above its median of 10× over this window — 10% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
24326327329028732332141122.2%9.1%Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 43% against the same quarter a year earlier

Going against it

  • profit dropped 16% year on year
  • net margin narrowed from 16.4% to 9.1%
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
41151385.729.1%
Q3 FY25
2024-12-31 · consolidated
32167538.0116.4%
Q2 FY25
2024-09-30 · consolidated
32369527.8616.0%
Q1 FY25
2024-06-30 · consolidated
28760456.8015.5%
Q4 FY24
2024-03-31 · consolidated
29062456.4915.6%
Q3 FY24
2023-12-31 · consolidated
27358446.5616.0%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+2.7%
Versus 200-day average+13.5%
Below 52-week high-6.8%
Above 52-week low+29.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)41.0
Higher closes in last 52 of 5
Six-month return+18.61%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.45%
Volume versus 20-day0.4x
Median daily turnoverRs 6.0 cr

Peers

Healthcare · 67 classified companies
JLHL trades at 10.9× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 75%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA456,44338.3−2.64%+21.54%363.8
DIVISLAB227,82077.9+17.69%+40.46%315.4
TORNTPHARM165,72780.1−3.33%+36.66%212.0
APOLLOHOSP125,00557.6−1.91%+13.16%257.5
CIPLA115,70034.5+2.81%−8.73%119.7
ZYDUSLIFE111,77625.5+0.56%+12.44%112.7
LUPIN100,67718.1−8.12%+16.52%259.0
MANKIND98,45947.6−6.78%−6.26%81.8
DRREDDY98,08730.8+0.72%−6.30%205.2
LAURUSLABS97,35389.3+14.90%+109.51%286.4
MAXHEALTH97,32466.8−7.77%−13.93%185.4
JLHL2,03110.9−1.64%+6.97%6.0
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet